Schröder intervenes in drug savings package. Sparing for the industry, more restrictions for us physicians?
Jentsch, P.
MMW Fortschritte der Medizin 143(44): 50-51
2001
ISSN/ISBN: 1438-3276 PMID: 11732397 Document Number: 535775
Document emailed within 1 workday
Related Documents
Hallager, K. 2004: Physicians and drug industry Ugeskrift for Laeger 166(21): 2069Håkansson, J. 2003: "Others are influenced, not me!" Physicians are often not aware how manipulated they are by drug industry Lakartidningen 100(50): 4158-4159
Edstedt, U. 1978: Direct contact between industry and physicians is required for successful drug research Nordisk Medicin 93(3-4): 86-87
Lewis, F. 2001: Tax savings opportunities for physicians Michigan Medicine 100(2): 10-11
Boyer, M.M. 1998: Surcharge savings estimated at $24 million for PA physicians Pennsylvania Medicine 101(1): 1-2
Robinson, D.S. 1994: Psychotropic drug labeling: regulatory, pharmaceutical industry, and clinical issues and perspectives. a pharmaceutical industry perspective on drug labeling Psychopharmacology Bulletin 30(1): 23-25
Wehrwein, P. 1999: Shrinking managed care savings may give physicians greater voice Managed Care 8(1): 24-6 28-30
Hoddad, P.J. 2013: What physicians need to know about Accountable Care Organizations under the Medicare Shared Savings Program Michigan Medicine 112(1): 20-22
Haas-Wilson, D. 1993: The economic impact of state restrictions on abortion: parental consent and notification laws and Medicaid funding restrictions Journal of Policy Analysis and Management: 12(3): 498-511
Moores, J. 1988: The impact of Drug Traffic restrictions on standards of care Professional Nurse 3(11): 466-472
Laroche, M-Laure.; Merle, L. 2005: Generic drug savings Annals of Internal Medicine 143(11): 844
Boisseree, V.R.; Keith, J.C.; Little, D.L. 1984: The valium project: diagnostic restrictions as a utilization control in a Medicaid drug program Health Care Financing Review 5(3): 133-138
Argüello, B.; Fernández-Llimós, F. 2007: Professionals' access to drug package inserts Atencion Primaria 39(4): 219
Barna, P. 1981: Package inserts provide inadequate drug information New England Journal of Medicine 304(19): 1178
Miquel, A.V.; Ortín Font, F.; Marrugat, J.; Pavesi, M. 2000: Assessment of the comprehension of new rephrasing drug package inserts Medicina Clinica 115(11): 410-417
Gottberg, L. 1991: FASS (Swedish drug index) 1991. Restrictions of basic current treatment of asthma in pregnant women Lakartidningen 88(14): 1272-1273
Lerch, C. 1994: Responsibility for patient education in drug therapy from the viewpoint of the drug industry Zeitschrift für Arztliche Fortbildung 88(12): 1055-1060
Heymann, W.R. 2000: Diltiazem-induced drug eruption sparing seborrheic keratoses Cutis 66(2): 129-130
Rolston, L.; Bresch, J.; Engh, G.; Franz, A.; Kreuzer, S.; Nadaud, M.; Puri, L.; Wood, D. 2007: Bicompartmental knee arthroplasty: a bone-sparing, ligament-sparing, and minimally invasive alternative for active patients Orthopedics 30(8 Suppl): 70-73
Armetti, L. 1999: Round table: The Italian Pharmacology Society and the drug industry: new processes in drug discovery and the contribution of universities Bollettino chimico farmaceutico 138(11): 596-598